A survey of IoT security based on a layered architecture of sensing and data analysis

The Internet of Things (IoT) is leading today’s digital transformation. Relying on a combination of technologies, protocols, and devices such as wireless sensors and newly developed wearable and implanted sensors, IoT is changing every aspect of daily life, especially recent applications in digital healthcare. IoT incorporates various kinds of hardware, communication protocols, and services. This IoT diversity can be viewed as a double-edged sword that provides comfort to users but can lead also to a large number of security threats and attacks. In this survey paper, a new compacted and optimized architecture for IoT is proposed based on five layers. Likewise, we propose a new classification of security threats and attacks based on new IoT architecture. The IoT architecture involves a physical perception layer, a network and protocol layer, a transport layer, an application layer, and a data and cloud services layer. First, the physical sensing layer incorporates the basic hardware used by IoT. Second, we highlight the various network and protocol technologies employed by IoT, and review the security threats and solutions. Transport protocols are exhibited and the security threats against them are discussed while providing common solutions. Then, the application layer involves application protocols and lightweight encryption algorithms for IoT. Finally, in the data and cloud services layer, the main important security features of IoT cloud platforms are addressed, involving confidentiality, integrity, authorization, authentication, and encryption protocols. The paper is concluded by presenting the open research issues and future directions towards securing IoT, including the lack of standardized lightweight encryption algorithms, the use of machine-learning algorithms to enhance security and the related challenges, the use of Blockchain to address security challenges in IoT, and the implications of IoT deployment in 5G and beyond

Towards securing machine learning models against membership inference attacks

From fraud detection to speech recognition, including price prediction, Machine Learning (ML) applications are manifold and can significantly improve different areas. Nevertheless, machine learning models are vulnerable and are exposed to different security and privacy attacks. Hence, these issues should be addressed while using ML models to preserve the security and privacy of the data used. There is a need to secure ML models, especially in the training phase to preserve the privacy of the training datasets and to minimise the information leakage. In this paper, we present an overview of ML threats and vulnerabilities, and we highlight current progress in the research works proposing defence techniques against ML security and privacy attacks. The relevant background for the different attacks occurring in both the training and testing/inferring phases is introduced before presenting a detailed overview of Membership Inference Attacks (MIA) and the related countermeasures. In this paper, we introduce a countermeasure against membership inference attacks (MIA) on Conventional Neural Networks (CNN) based on dropout and L2 regularization. Through experimental analysis, we demonstrate that this defence technique can mitigate the risks of MIA attacks while ensuring an acceptable accuracy of the model. Indeed, using CNN model training on two datasets CIFAR-10 and CIFAR-100, we empirically verify the ability of our defence strategy to decrease the impact of MIA on our model and we compare results of five different classifiers. Moreover, we present a solution to achieve a trade-off between the performance of the model and the mitigation of MIA attack

Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations

<p>Abstract</p> <p>Background</p> <p>Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumour necrosis factor cytokine family that induces apoptosis upon binding to its death domain containing receptors, TRAIL receptor 1 (DR4) and TRAIL receptor 2 (DR5). Expression of TRAIL receptors is higher in colorectal carcinoma (CRC) as compared to normal colorectal mucosa and targeted therapy with TRAIL leads to preferential killing of tumor cells sparing normal cells.</p> <p>Methods</p> <p>We investigated the expression of TRAIL and its receptors in a tissue microarray cohort of 448 Middle Eastern CRC. We also studied the correlation between TRAIL receptors and various clinico-pathological features including key molecular alterations and overall survival.</p> <p>Results</p> <p>CRC subset with TRAIL-R1 expression was associated with a less aggressive phenotype characterized by early stage (p = 0.0251) and a histology subtype of adenocarcinomas (p = 0.0355). Similarly CRC subset with TRAIL-R2 expression was associated with a well-differentiated tumors (p < 0.0001), histology subtype of adenocarcinomas (p = 0.0010) and tumors in left colon (p = 0.0009). Over expression of pro apoptotic markers: p27^KIP1and KRAS4A isoforms was significantly higher in CRC subset with TRAIL-R1 and TRAIL-R2 expression; TRAIL-R1 expression was also associated with cleaved caspase-3(p = 0.0011). Interestingly, TRAIL-R2 expression was associated with a microsatellite stable (MS--S/L) phenotype (p = 0.0003) and with absence of KRAS mutations (p = 0.0481).</p> <p>Conclusion</p> <p>TRAIL-R1 expression was an independent prognostic marker for better survival in all CRC samples and even in the CRC group that received adjuvant therapy. The biological effects of TRAIL in CRC models, its enhancement of chemosensitivity towards standard chemotherapeutic agents and the effect of endogenous TRAIL receptor levels on survival make TRAIL an extremely attractive therapeutic target.</p

Systematic Review of Medicine-Related Problems in Adult Patients with Atrial Fibrillation on Direct Oral Anticoagulants

New oral anticoagulant agents continue to emerge on the market and their safety requires assessment to provide evidence of their suitability for clinical use. There-fore, we searched standard databases to summarize the English language literature on medicine-related problems (MRPs) of direct oral anticoagulants DOACs (dabigtran, rivaroxban, apixban, and edoxban) in the treatment of adults with atri-al fibrillation. Electronic databases including Medline, Embase, International Pharmaceutical Abstract (IPA), Scopus, CINAHL, the Web of Science and Cochrane were searched from 2008 through 2016 for original articles. Studies pub-lished in English reporting MRPs of DOACs in adult patients with AF were in-cluded. Seventeen studies were identified using standardized protocols, and two reviewers serially abstracted data from each article. Most articles were inconclusive on major safety end points including major bleeding. Data on major safety end points were combined with efficacy. Most studies inconsistently reported adverse drug reactions and not adverse events or medication error, and no definitions were consistent across studies. Some harmful drug effects were not assessed in studies and may have been overlooked. Little evidence is provided on MRPs of DOACs in patients with AF and, therefore, further studies are needed to establish the safety of DOACs in real-life clinical practice

Medication use and medicine-related problems (MRPs) in South Asian and Middle Eastern patients with chronic diseases in the UK

Non peer reviewe

South Asian and Middle Eastern patients' perspectives on medicine-related problems in the United Kingdom

There has been little research which specifically examines medicine use among South Asian (SA) and Middle Eastern (ME) groups, although evidence suggests that medicine-related needs may be poorly met for these groups. To describe medicine-related problems (MRPs) experienced by SA and ME patients from their perspectives and identify possible contributory factors that may be specific to their cultures. The data were collected in seven pharmacies in London, United Kingdom (UK). The study was a qualitative study. Patients were from SA and ME origins, aged over 18 and prescribed three or more regular medicines. Patients were identified when presenting with a prescription. The data were collected in 80 face-to-face semi-structured interviews using Gordon's MRPs tool. Interviews were audiotaped, transcribed verbatim and analysed thematically using Gordon's coding frame and Nvivo 10 software. Main outcome measure Describing MRPs experienced by SA and ME patients from their perspectives and identifying possible contributory factors that may be specific to their cultures. Results Eighty participants (61 % male) had mean (SD) age 58 (13.4) years and a mean (SD) of 8 (4) medicines. Interviews revealed that several factors contributed to the development of MRPs; some appeared to be specific to SA and ME cultures and others were similar to the general population. The factors that were reported to be specific to SA and ME groups comprised religious practices and beliefs, use of non-prescription medicines, extent of family support, and travelling abroad-to patient's homeland or to take religious journeys. Illiteracy, language and communication barriers, lack of translated resources, perceptions of healthcare providers, and difficulty consulting a doctor of the same gender may also contribute to the problems. Many of these factors could be expected to influence patient's safety, adherence, and informed decision-making. This study demonstrated that SA and ME patients have their own problems and needs regarding both medicine use and service access. By uncovering particular problems experienced by these groups, the study can inform healthcare professionals to support SA and ME patients in the use of their medicinesPeer reviewe

A Scalable Digit-Parallel Polynomial Multiplier Architecture for NIST-Standardized Binary Elliptic Curves

This work presents a scalable digit-parallel finite field polynomial multiplier architecture with a digit size of 32 bits for NIST-standardized binary elliptic fields. First, a dedicated digit-parallel architecture is proposed for each binary field recommended by NIST, i.e., 163, 233, 283, 409 and 571. Then, a scalable architecture having support for all variants of binary fields of elliptic curves is proposed. For performance investigation, we have compared dedicated multiplier architectures with scalable design. After this, the dedicated and scalable architectures are compared with the most relevant state-of-the-art multipliers. All multiplier architectures are implemented in Verilog HDL using the Vivado IDE tool. The implementation results are reported on a 28 nm Virtex-7 FPGA technology. The dedicated multipliers utilize slices of 1182 (for m=163), 1451 (for m=233), 1589 (for m=283), 2093 (for m=409) and 3451 (for m=571). Moreover, our dedicated designs can operate at a maximum frequency of 500, 476, 465, 451 and 443 MHz. Similarly, for all supported binary fields, our scalable architecture (i) utilizes 3753 slices, (ii) achieves 305 MHz clock frequency, (iii) takes 0.013 μs for one finite field multiplication and (iv) consumes 3.905 W power. The proposed scalable digit-parallel architecture is more area-efficient than most recent state-of-the-art multipliers. Consequently, the reported results and comparison to the state of the art reveal that the proposed architectures are well suited for cryptographic applications

High-dose interleukin-2 therapy related adverse events and implications on imaging

High-dose interleukin-2 (HDIL-2) therapy was initially approved by the U.S. Food and Drug Administration for metastatic renal cell carcinoma (mRCC) and metastatic melanoma. IL-2 is able to promote CD8+ T cell and natural killer (NK) cell cytotoxicity to increase tumoricidal activity of the innate immune system. HDIL-2 therapy is associated with a wide spectrum of immune-related adverse events (irAEs) that can be radiologically identified. HDIL-2 toxicity can manifest in multiple organ systems, most significantly leading to cardiovascular, abdominal, endocrine, and neurological adverse events. The collective impact of the irAEs and the rise of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors led to the demise of HDIL-2 as a primary therapy for mRCC and metastatic melanoma. However, with innovation in ICIs and the creation of mutant IL-2 conjugates, there has been a drive for combination therapy. Knowledge of the HDIL-2 therapy and HDIL-2 related adverse events with radiology relevance is critical in diagnostic image interpretation

Meeting report from the joint IARC-NCI international cancer seminar series: a focus on colorectal cancer

Despite significant progress in our understanding of the etiology, biology and genetics of colorectal cancer, as well as important clinical advances, it remains the third most frequently diagnosed cancer worldwide and is the second leading cause of cancer death. Based on demographic projections, the global burden of colorectal cancer would be expected to rise by 72% from 1.8 million new cases in 2018 to over 3 million in 2040 with substantial increases anticipated in low and middle income countries. In this meeting report, we summarize the content of a joint workshop led by the National Cancer Institute (NCI) and the International Agency for Research on Cancer (IARC) which was held to summarize the important achievements that have been made in our understanding of colorectal cancer etiology, genetics, early detection and treatment and to identify key research questions that remain to be addressed

Coexpression of activated c-met and death receptor 5 predicts better survival in colorectal carcinoma

Dysregulated overexpression of hepatocyte growth factor and its receptor, c-Met, has been reported in various cancers, but its role in colorectal carcinoma (CRC) has not been elucidated. Therefore, we investigated the role of phosphorylated Met (p-Met) in Middle Eastern CRC patient samples and cell lines. The p-Met was overexpressed in 80.8% of CRCs and strongly associated with the expression of p-AKT, DR5, and Ki-67 by immunohistochemistry. Coexpression of p-Met and DR5 was seen in 53.1% of CRC cases and was associated with a less aggressive phenotype, characterized by a histological subtype of adenocarcinomas, well-differentiated tumors, and was an independent prognostic marker for better overall survival. PHA665752, a selective p-Met inhibitor, induced apoptosis in CRC cells via inactivation of c-Met and AKT. PHA665752 treatment also caused increased expression of DR5 via generation of reactive oxygen species, and combination treatment with tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) and PHA665752 induced significant apoptosis. In vivo, cotreatment of a CRC xenograft with PHA665752 and TRAIL significantly reduced tumor volume and weight. These data demonstrate a significant correlation between p-Met and DR5 in patients with CRC. Furthermore, inhibition of p-Met signaling by PHA665752 in combination with TRAIL significantly inhibited cell growth and induced apoptosis in CRC cell lines, suggesting that this may have significant clinical implications as a therapeutic target in the treatment of CRC